v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (56,340,774) $ (37,718,286)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,709,783 2,429,550
Loss on disposal of fixed assets 12,478 27,017
Stock-based compensation 2,166,940 2,014,669
Gain on transfer of plasma center assets 0 (11,527,421)
Amortization of debt discount 1,344,344 719,607
Loss on extinguishment of debt 0 9,962,495
Amortization of license revenue (107,125) (107,125)
Changes in operating assets and liabilities:    
Accounts receivable (2,864,617) (5,923,040)
Inventories (16,687,794) (21,870,736)
Prepaid expenses and other current assets (1,252,828) 44,081
Deposits and other assets (74,335) 104,687
Accounts payable (1,194,820) 3,059,511
Accrued expenses 2,617,472 1,326,363
Deferred revenue 0 1,055,076
Other current and non-current liabilities (112,246) (137,916)
Net cash used in operating activities (69,783,522) (56,541,468)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (9,128,359) (2,217,542)
Proceeds from the sale of property and equipment 2,000 0
Net cash used in investing activities (9,126,359) (2,217,542)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Principal payments on notes payable 0 (30,000,000)
Payment of end of term fee 0 (2,760,000)
Payment of debt refinancing fees 0 (6,499,867)
Proceeds from issuance of note payable 12,500,000 72,500,000
Payment of debt issuance costs 0 (1,679,661)
Proceeds from the issuance of common stock, net of offering expenses 99,343,207 48,397,088
Proceeds from the exercise of stock options 13,432 75,048
Payments on finance lease obligations (23,848) (22,298)
Net cash provided by financing activities 111,832,791 80,010,310
Net increase in cash and cash equivalents 32,922,910 21,251,300
Cash and cash equivalents, including restricted cash - beginning of period 26,752,135 26,754,852
Cash and cash equivalents - end of period $ 59,675,045 $ 48,006,152

Source